{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:57Z","timestamp":1793316297752,"version":"4.5.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neubiorev.2025.106204","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T07:59:18Z","timestamp":1746777558000},"page":"106204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-5223","authenticated-orcid":false,"given":"Omer A.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Petranker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2025.106204_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00213-018-5106-2","article-title":"Microdosing psychedelics: personality, mental health, and creativity differences in microdosers","volume":"236","author":"Anderson","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106204_bib2","first-page":"201","article-title":"Hallucinogens in drug discrimination","author":"Baker","year":"2018","journal-title":"Behav. Neurobiol. Psychedelic Drugs"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/17425255.2022.2085552","article-title":"CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia","volume":"18","author":"Ballester","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib4","doi-asserted-by":"crossref","unstructured":"Barnett, J.H., Todd, K.T., Benetatos, J., Rabichow, B.E., Gibson, K.A., Olney, K.C., & Fryer, J.D. (2024). Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathways. bioRxiv, 2024-12.","DOI":"10.1101\/2024.12.16.628764"},{"issue":"10","key":"10.1016\/j.neubiorev.2025.106204_bib5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0378-8741(82)90013-7","article-title":"Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, USA","volume":"5","author":"Beug","year":"1982","journal-title":"J. Ethnopharmacol."},{"issue":"11","key":"10.1016\/j.neubiorev.2025.106204_bib7","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.3390\/ijms23115968","article-title":"Advantages and limitations of animal schizophrenia models","volume":"23","author":"Bia\u0142o\u0144","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib8","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1503\/jpn.220090","article-title":"Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies","volume":"47","author":"Borgland","year":"2022","journal-title":"J. Psychiatry Neurosci."},{"issue":"11","key":"10.1016\/j.neubiorev.2025.106204_bib9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s41380-023-02391-7","article-title":"High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin","volume":"29","author":"Braun","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giaa056","article-title":"Recommendations to enhance rigor and reproducibility in biomedical research","volume":"9","author":"Brito","year":"2020","journal-title":"GigaScience"},{"issue":"7","key":"10.1016\/j.neubiorev.2025.106204_bib12","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1021\/acschemneuro.8b00692","article-title":"Chronic, intermittent microdoses of the psychedelic N, N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents","volume":"10","author":"Cameron","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.neubiorev.2025.106204_bib13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/acschemneuro.8b00134","article-title":"Effects of N, N-dimethyltryptamine on rat behaviors relevant to anxiety and depression","volume":"9","author":"Cameron","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"6579","key":"10.1016\/j.neubiorev.2025.106204_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/acs.chemrestox.9b00335","article-title":"Use of zebrafish in drug discovery toxicology","volume":"33","author":"Cassar","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41398-022-02039-0","article-title":"Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study","volume":"12","author":"Cavanna","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106204_bib17","first-page":"1","article-title":"Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms","author":"Conn","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib18","doi-asserted-by":"crossref","DOI":"10.24839\/2325-7342.JN27.3.197","article-title":"Lysergic Acid Diethylamide Produces Anxiogenic Effects in the Rat Light\/Dark Test and Elevated Plus Maze","volume":"27","author":"Conway","year":"2022","journal-title":"Psi Chi J. Psychol. Res."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib19","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.neuron.2008.03.001","article-title":"Behavioral phenotyping strategies for mutant mice","volume":"57","author":"Crawley","year":"2008","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s13063-024-08384-3","article-title":"LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder","volume":"25","author":"Daldegan-Bueno","year":"2024","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s41386-022-01301-9","article-title":"Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline","volume":"47","author":"De Gregorio","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106204_bib22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020705118","article-title":"Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission","volume":"118","author":"De Gregorio","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neubiorev.2025.106204_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors","volume":"113","author":"De Gregorio","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13143","article-title":"Repeated low doses of LSD in healthy adults: A placebo-controlled, dose\u2013response study","volume":"27","author":"de Wit","year":"2022","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.643028","article-title":"Sex proportionality in pre-clinical and clinical trials: an evaluation of 22 marketing authorization application dossiers submitted to the European Medicines Agency","volume":"8","author":"Dekker","year":"2021","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.22270\/ajprd.v7i6.616","article-title":"The stages of drug discovery and development process","volume":"7","author":"Deore","year":"2019","journal-title":"Asian J. Pharm. Res. Dev."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s40814-023-01399-8","article-title":"An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)","volume":"9","author":"Donegan","year":"2023","journal-title":"Pilot Feasibility Stud."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/jnc.16070","article-title":"Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors","volume":"168","author":"Dunham","year":"2024","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41398-023-02414-5","article-title":"Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding","volume":"13","author":"Effinger","year":"2023","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41398-022-02103-9","article-title":"Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice","volume":"12","author":"Fadahunsi","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106204_bib31","first-page":"1","article-title":"Rapid and sustained antidepressant effects of vaporized N, N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression","author":"Falchi-Carvalho","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ae\/tmad063","article-title":"Flies on\u2019shrooms: studying the psychotherapeutic potential of psilocybin using drosophila","volume":"69","author":"Faraone","year":"2023","journal-title":"Am. \u00c8ntomol."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41398-024-03103-7","article-title":"Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats","volume":"14","author":"Fisher","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd3252","article-title":"Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes","volume":"10","author":"Force","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neubiorev.2025.106204_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/jppr.1921","article-title":"3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy: what the pharmacist needs to know","author":"Gallo","year":"2024","journal-title":"J. Pharm. Pract. Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881121991822","article-title":"Optimal dosing for psilocybin pharmacotherapy: considering weight-adjusted and fixed dosing approaches","volume":"35","author":"Garcia-Romeu","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106204_bib37","first-page":"464","article-title":"A brief historical overview of psychedelic research","volume":"9","author":"Geyer","year":"2024","journal-title":"Biol. Psychiatry.: Cogn. Neurosci. Neuroimag."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1021\/acsptsci.3c00192","article-title":"Comparative pharmacological effects of lisuride and lysergic acid diethylamide revisited","volume":"7","author":"Glatfelter","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/02791072.2022.2108356","article-title":"Naturalistic psychedelic use: a world apart from clinical care","volume":"55","author":"Glynos","year":"2023","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neubiorev.2025.106204_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res."},{"issue":"26","key":"10.1016\/j.neubiorev.2025.106204_bib41","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","article-title":"Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex","volume":"23","author":"Gonz\u00e1lez-Maeso","year":"2003","journal-title":"J. Neurosci."},{"issue":"18","key":"10.1016\/j.neubiorev.2025.106204_bib42","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/appi.ajp.20221043","article-title":"Must psilocybin always \u201cassist psychotherapy\u201d?","volume":"181","author":"Goodwin","year":"2024","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bbr.2010.05.039","article-title":"Characterization of behavioral and endocrine effects of LSD on zebrafish","volume":"214","author":"Grossman","year":"2010","journal-title":"Behav. brain Res."},{"key":"10.1016\/j.neubiorev.2025.106204_bib45","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbr.2013.08.045","article-title":"Animal models of the serotonin syndrome: a systematic review","volume":"256","author":"Haberzettl","year":"2013","journal-title":"Behav. brain Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib46","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1038\/s41598-024-54676-8","article-title":"Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish","volume":"14","author":"Hagen","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2025.106204_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115531","article-title":"Psilocybin-assisted therapy for depression: a systematic review and meta-analysis","author":"Haikazian","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neubiorev.2025.106204_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib49","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.190806","article-title":"An empirical assessment of transparency and reproducibility-related research practices in the social sciences (2014\u20132017)","volume":"7","author":"Hardwicke","year":"2020","journal-title":"R. Soc. Open Sci."},{"issue":"12","key":"10.1016\/j.neubiorev.2025.106204_bib50","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib51","doi-asserted-by":"crossref","unstructured":"Hartogsohn, I. (2024). Set and setting for psychedelic harm reduction.","DOI":"10.1007\/7854_2024_509"},{"issue":"12","key":"10.1016\/j.neubiorev.2025.106204_bib52","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1007\/s00213-022-06249-8","article-title":"Set and setting in microdosing: an oft-overlooked principle","volume":"239","author":"Hartogsohn","year":"2022","journal-title":"Psychopharmacology"},{"issue":"17","key":"10.1016\/j.neubiorev.2025.106204_bib53","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib54","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106204_bib55","first-page":"240","article-title":"Psychotomimetic drugs","volume":"8","author":"Hofmann","year":"1959","journal-title":"Acta Physiol. Et. Pharmacol. Neerl."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0091-3057(95)02126-4","article-title":"A review of the validity and variability of the elevated plus-maze as an animal model of anxiety","volume":"54","author":"Hogg","year":"1996","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2025.106204_bib57","first-page":"1","article-title":"Safety pharmacology of acute LSD administration in healthy subjects","author":"Holze","year":"2022","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FBP.0000000000000394","article-title":"Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats","volume":"29","author":"Horsley","year":"2018","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.891512","article-title":"Chronic treatment with psilocybin decreases changes in body weight in a rodent model of obesity","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2025.106204_bib60","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","article-title":"Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study","volume":"41","author":"Hutten","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106204_bib62","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1039\/C8TX00072G","article-title":"Evidence for cardiotoxicity associated with sertraline in rats","volume":"7","author":"Ilgin","year":"2018","journal-title":"Toxicol. Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0006-8993(77)90423-1","article-title":"Behavioral effects of LSD in the cat: Proposal of an animal behavior model for studying the actions of hallucinogenic drugs","volume":"132","author":"Jacobs","year":"1977","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0269881120959614","article-title":"Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin","volume":"35","author":"Jefsen","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1017\/neu.2019.15","article-title":"Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat","volume":"31","author":"Jefsen","year":"2019","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neubiorev.2025.106204_bib66","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00213-014-3825-6","article-title":"The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes","volume":"232","author":"Jiang","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106204_bib67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib68","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050759","article-title":"Sex matters in preclinical research","volume":"17","author":"Justice","year":"2024","journal-title":"Dis. Models Mech."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib69","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41598-021-81446-7","article-title":"Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing","volume":"11","author":"Kaertner","year":"2021","journal-title":"Scientific reports"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib70","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/zeb.2012.0861","article-title":"Towards a comprehensive catalog of zebrafish behavior 1.0 and beyond","volume":"10","author":"Kalueff","year":"2013","journal-title":"Zebrafish"},{"issue":"21","key":"10.1016\/j.neubiorev.2025.106204_bib71","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1111\/bph.14539","article-title":"Sex bias in preclinical research and an exploration of how to change the status quo","volume":"176","author":"Karp","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib72","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00228-003-0701-4","article-title":"Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study","volume":"59","author":"Kawanishi","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib73","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics","volume":"32","author":"Kelmendi","year":"2022","journal-title":"Curr. Biol."},{"issue":"9","key":"10.1016\/j.neubiorev.2025.106204_bib74","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1038\/s41380-023-02280-z","article-title":"Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats","volume":"28","author":"Kiilerich","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib75","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/JOE-19-0561","article-title":"Sex steroid hormones differentially regulate CYP2D in female wild-type and CYP2D6-humanized mice","volume":"245","author":"Konstandi","year":"2020","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320950567","article-title":"The therapeutic potential of microdosing psychedelics in depression","volume":"10","author":"Kuypers","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2025.106204_bib77","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: More questions than answers? an overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib78","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106204_bib79","article-title":"Acute psilocybin increased cortical activities in rats","volume":"17","author":"Liu","year":"2023","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib80","first-page":"51073","article-title":"Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review","volume":"26","author":"Lo","year":"2024","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.neubiorev.2025.106204_bib81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fnbeh.2018.00190","article-title":"It\u2019s tea time: Interference of ayahuasca brew on discriminative learning in zebrafish","volume":"12","author":"Lobao-Soares","year":"2018","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106204_bib82","first-page":"71","article-title":"Sex differences in associations between CYP2D6 phenotypes and response to opioid analgesics","author":"Lopes","year":"2020","journal-title":"Pharm. Pers. Med."},{"key":"10.1016\/j.neubiorev.2025.106204_bib83","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-002-1183-2","article-title":"Biological basis of sex differences in drug abuse: preclinical and clinical studies","volume":"164","author":"Lynch","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106204_bib84","doi-asserted-by":"crossref","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","article-title":"Therapeutic use of psilocybin: Practical considerations for dosing and administration","volume":"13","author":"MacCallum","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106204_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.05.014","article-title":"Let\u2019s talk about sex: Differences in drug therapy in males and females","volume":"175","author":"Madla","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.neubiorev.2025.106204_bib86","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.neubiorev.2025.106204_bib87","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/17425255.2018.1499725","article-title":"Misconceptions and issues regarding allometric scaling during the drug development process","volume":"14","author":"Mahmood","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib88","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/BF00426460","article-title":"Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens","volume":"73","author":"Marini","year":"1981","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib89","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0014-2999(81)90359-9","article-title":"On the specificity of a cat behavior model for the study of hallucinogens","volume":"70","author":"Marini","year":"1981","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2025.106204_bib90","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41386-020-0694-z","article-title":"Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse","volume":"45","author":"Meinhardt","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1096\/fj.201600781r","article-title":"Considering sex as a biological variable in preclinical research","volume":"31","author":"Miller","year":"2016","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib92","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","article-title":"Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis","volume":"78","author":"Milosavljevi\u0107","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106204_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13041-020-0552-2","article-title":"No raw data, no science: another possible source of the reproducibility crisis","volume":"13","author":"Miyakawa","year":"2020","journal-title":"Mol. brain"},{"key":"10.1016\/j.neubiorev.2025.106204_bib94","doi-asserted-by":"crossref","first-page":"1200430","DOI":"10.3389\/fphar.2023.1200430","article-title":"Impact of CYP2D6 genotype on opioid use disorder deprescription: an observational prospective study in chronic pain with sex-differences","volume":"14","author":"Muriel","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pbr.2018.08.003","article-title":"The renaissance in psychedelic research: what do preclinical models have to offer","volume":"242","author":"Murnane","year":"2018","journal-title":"Prog. brain Res."},{"key":"10.1016\/j.neubiorev.2025.106204_bib96","first-page":"1","article-title":"MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers","volume":"22","author":"Murphy","year":"2021","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib97","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","article-title":"Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial","volume":"94","author":"Murphy","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib99","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib100","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1124\/pharmrev.122.000590","article-title":"Animal behavior in psychedelic research","volume":"74","author":"Odland","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neubiorev.2025.106204_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173903","article-title":"Mescaline-induced behavioral alterations are mediated by 5-HT2A and 5-HT2C receptors in rats","volume":"245","author":"Olejn\u00edkov\u00e1-Ladislavov\u00e1","year":"2024","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib102","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000321803","article-title":"Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics","volume":"63","author":"P\u00e1len\u00ed\u010dek","year":"2011","journal-title":"Neuropsychobiology"},{"issue":"8","key":"10.1016\/j.neubiorev.2025.106204_bib103","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study","volume":"29","author":"Peck","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.neubiorev.2025.106204_bib104","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3389\/fpsyg.2020.01681","article-title":"Psychedelic research and the need for transparency: polishing Alice\u2019s looking glass","volume":"11","author":"Petranker","year":"2020","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib105","doi-asserted-by":"crossref","first-page":"1217102","DOI":"10.3389\/fpsyt.2024.1217102","article-title":"Keeping the promise: a critique of the current state of microdosing research","volume":"15","author":"Petranker","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0269881120953994","article-title":"Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention","volume":"36","author":"Petranker","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.670479","article-title":"Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician","volume":"12","author":"Podyacheva","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104706","article-title":"The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955\u20132021) and recommendations for the field","volume":"139","author":"Polito","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neubiorev.2025.106204_bib109","doi-asserted-by":"crossref","DOI":"10.1177\/02698811241254831","article-title":"Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research","author":"Polito","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1556\/2054.2023.00260","article-title":"Microdosing psychedelics: The segregation of spiritual and scientific narratives within the r\/microdosing online community","volume":"7","author":"Pop","year":"2023","journal-title":"J. Psychedelic Stud."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib112","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/15563650.2020.1839662","article-title":"Fatal serotonin syndrome: a systematic review of 56 cases in the literature","volume":"59","author":"Prakash","year":"2021","journal-title":"Clin. Toxicol."},{"issue":"1-3","key":"10.1016\/j.neubiorev.2025.106204_bib113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","article-title":"The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review","volume":"463","author":"Prut","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib114","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fnbeh.2014.00180","article-title":"The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat","volume":"8","author":"Rambousek","year":"2014","journal-title":"Front. Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0149-7634(97)00001-8","article-title":"Stress and emotionality: a multidimensional and genetic approach","volume":"22","author":"Ramos","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib116","doi-asserted-by":"crossref","first-page":"17475","DOI":"10.1038\/s41598-023-44153-z","article-title":"Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences","volume":"13","author":"Rieser","year":"2023","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib117","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/0269881120908004","article-title":"Microdosing psychedelics: aemographics, practices, and psychiatric comorbidities","volume":"34","author":"Rosenbaum","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib118","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib119","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/02698811231225609","article-title":"Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: comparison to known cardiotoxins","volume":"38","author":"Rouaud","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12888-023-04628-9","article-title":"Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health","volume":"23","author":"Ryan","year":"2023","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib121","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/pha0000253","article-title":"Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats","volume":"27","author":"Sakloth","year":"2019","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib122","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0031-6989(74)80037-8","article-title":"Facilitation of avoidance behaviour by LSD-25 and mescaline in hamsters","volume":"6","author":"Sansone","year":"1974","journal-title":"Pharmacol. Res. Commun."},{"key":"10.1016\/j.neubiorev.2025.106204_bib123","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fnbeh.2017.00139","article-title":"Behavioral changes over time following ayahuasca exposure in zebrafish","volume":"11","author":"Savoldi","year":"2017","journal-title":"Front. Behav. Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib124","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/17425255.4.4.413","article-title":"Sex-specific differences in CYP450 isoforms in humans","volume":"4","author":"Scandlyn","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib125","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","article-title":"Long-lasting subjective effects of LSD in normal subjects","volume":"235","author":"Schmid","year":"2018","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.neubiorev.2025.106204_bib126","doi-asserted-by":"crossref","first-page":"bqae083","DOI":"10.1210\/endocr\/bqae083","article-title":"Potential differences in psychedelic actions based on biological sex","volume":"165","author":"Shadani","year":"2024","journal-title":"Endocrinology"},{"key":"10.1016\/j.neubiorev.2025.106204_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114627","article-title":"Effects of psilocybin on body weight, body composition, and metabolites in male and female mice","volume":"284","author":"Shakir","year":"2024","journal-title":"Physiol. Behav."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib128","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1476-5381.2009.00267.x","article-title":"To scale or not to scale: the principles of dose extrapolation","volume":"157","author":"Sharma","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"8023","key":"10.1016\/j.neubiorev.2025.106204_bib129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","article-title":"Psilocybin desynchronizes the human brain","volume":"632","author":"Siegel","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.neubiorev.2025.106204_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115349","article-title":"Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: a systematic review and individual participant data meta-analysis","author":"Simonsson","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neubiorev.2025.106204_bib131","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.psychres.2018.12.053","article-title":"Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?","volume":"271","author":"Solomon","year":"2019","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib132","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/02698811221131994","article-title":"Body mass index (BMI) does not predict responses to psilocybin","volume":"37","author":"Spriggs","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib133","series-title":"Psilocybin mushrooms of the world: an identification guide","author":"Stamets","year":"1996"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib134","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib135","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.neuint.2013.02.018","article-title":"Perspectives on experimental models of serotonin syndrome in zebrafish","volume":"62","author":"Stewart","year":"2013","journal-title":"Neurochem. Int."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106204_bib136","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/0269881121998322","article-title":"Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies","volume":"35","author":"Studerus","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106204_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2024.2446445","article-title":"Global trends in psychedelic microdosing: demographics, substance testing behavior, and patterns of use","author":"Syed","year":"2024","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neubiorev.2025.106204_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105381","article-title":"The zebrafish for preclinical psilocybin research","volume":"153","author":"Syed","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s44184-023-00044-9","article-title":"Managing expectations with psychedelic microdosing","volume":"2","author":"Syed","year":"2023","journal-title":"npj Ment. Health Res."},{"key":"10.1016\/j.neubiorev.2025.106204_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2023.08.001","article-title":"A perspective on psychedelic teratogenicity: the utility of Zebrafish models","author":"Syed","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neubiorev.2025.106204_bib141","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62878","article-title":"Self-blinding citizen science to explore psychedelic microdosing","volume":"10","author":"Szigeti","year":"2021","journal-title":"elife"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib142","doi-asserted-by":"crossref","first-page":"12107","DOI":"10.1038\/s41598-023-34938-7","article-title":"The difference between \u2018placebo group\u2019and \u2018placebo control\u2019: A case study in psychedelic microdosing","volume":"13","author":"Szigeti","year":"2023","journal-title":"Scientific Reports"},{"issue":"9","key":"10.1016\/j.neubiorev.2025.106204_bib143","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/02698811231190865","article-title":"The risk of chronic psychedelic and MDMA microdosing for valvular heart disease","volume":"37","author":"Tagen","year":"2023","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.neubiorev.2025.106204_bib144","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/genes11111295","article-title":"A review of the important role of CYP2D6 in pharmacogenomics","volume":"11","author":"Taylor","year":"2020","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.neubiorev.2025.106204_bib145","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/ph15070870","article-title":"Clinical impact of functional CYP2C19 and CYP2D6 gene variants on treatment with antidepressants in young people with depression: a Danish cohort study","volume":"15","author":"Thiele","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106204_bib146","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1021\/acschemneuro.2c00642","article-title":"Developmental neurotoxicity screen of psychedelics and other drugs of abuse in larval zebrafish (Danio rerio)","volume":"14","author":"Tombari","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib147","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0006-8993(77)90424-3","article-title":"Usefulness of an animal behavioral model in studying the duration of action of LSD and the onset and duration of tolerance to LSD in the cat","volume":"132","author":"Trulson","year":"1977","journal-title":"Brain Res."},{"key":"10.1016\/j.neubiorev.2025.106204_bib148","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231198466","article-title":"History repeating: guidelines to address common problems in psychedelic science","volume":"13","author":"van Elk","year":"2023","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib149","doi-asserted-by":"crossref","first-page":"10851","DOI":"10.1038\/s41598-021-90343-y","article-title":"Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis","volume":"11","author":"Vizeli","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41398-024-03074-9","article-title":"Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants","volume":"14","author":"Vizeli","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106204_bib151","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106204_bib152","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib153","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40814-024-01449-9","article-title":"PAM trial protocol: a randomised feasibility study of psychedelic microdosing\u2013assisted meaning-centred psychotherapy in advanced stage cancer patients","volume":"10","author":"Wells","year":"2024","journal-title":"Pilot Feasibility Stud."},{"key":"10.1016\/j.neubiorev.2025.106204_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105899","article-title":"Psychedelics: a review of their effects on recalled aversive memories and fear\/anxiety expression in rodents","author":"Werle","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"11","key":"10.1016\/j.neubiorev.2025.106204_bib155","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/bph.16315","article-title":"Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT2A and 5-HT1A receptors","volume":"181","author":"Werle","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"5309","key":"10.1016\/j.neubiorev.2025.106204_bib156","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106204_bib157","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0091-3057(81)90400-7","article-title":"Lack of specificity of an animal behavior model for hallucinogenic drug action","volume":"14","author":"White","year":"1981","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2025.106204_bib158","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-008-1356-8","article-title":"Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines","volume":"203","author":"Winter","year":"2009","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106204_bib159","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/13634615221129115","article-title":"Microdosing with classical psychedelics: Research trajectories and practical considerations","volume":"59","author":"Wong","year":"2022","journal-title":"Transcult. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106204_bib160","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","article-title":"Cardiovascular safety of psychedelic medicine: current status and future directions","volume":"75","author":"Ws\u00f3\u0142","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neubiorev.2025.106204_bib161","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00213-018-5119-x","article-title":"The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial","volume":"236","author":"Yanakieva","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106204_bib162","doi-asserted-by":"crossref","first-page":"1386321","DOI":"10.3389\/fpsyt.2024.1386321","article-title":"Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106204_bib163","doi-asserted-by":"crossref","first-page":"24955","DOI":"10.1038\/srep24955","article-title":"Systematic analysis of adverse event reports for sex differences in adverse drug events","volume":"6","author":"Yu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2025.106204_bib164","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11584550-000000000-00000","article-title":"Sex differences in 3, 4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans","volume":"50","author":"Yubero-Lahoz","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neubiorev.2025.106204_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1183740","article-title":"Psychedelic therapy in the treatment of addiction: the past, present and future","volume":"14","author":"Zafar","year":"2023","journal-title":"Front. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106204_bib166","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/toxins7041018","article-title":"Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice","volume":"7","author":"Zhuk","year":"2015","journal-title":"Toxins"},{"issue":"7299","key":"10.1016\/j.neubiorev.2025.106204_bib167","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/465690a","article-title":"Males still dominate animal studies","volume":"465","author":"Zucker","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neubiorev.2025.106204_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol. Sex. Differ."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425002040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425002040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:14:30Z","timestamp":1778386470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763425002040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":168,"alternative-id":["S0149763425002040"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106204","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106204"}}